Jiangxi Rimag (2522) H2 2025 earnings summary

Executive summary

• FY2025 revenue rose 14.8% YoY to RMB873.1m; annual net loss narrowed to RMB10.5m from RMB58.9m, while profit attributable to owners was RMB3.7m.

• Growth came from imaging solutions and digital-intelligent services, offsetting lower imaging center revenue; strategy centers on an integrated scenarios, data and AI ecosystem.

Financial highlights

• Gross profit increased 6.5% to RMB295.2m; operating profit was RMB24.8m versus an operating loss of RMB27.1m in 2024.

• Net loss narrowed to RMB10.5m from RMB58.9m; owners’ attributable result turned to profit of RMB3.7m from a loss of RMB45.9m.

• Non-IFRS EBITDA rose 30.8% YoY to RMB216.2m.

• Operating cash flow increased to RMB177.4m from RMB12.7m; year-end cash and cash equivalents reached RMB624.0m.

Outlook and guidance

• 2026 priorities include scaling domestic and overseas imaging services, commercializing data assets, advancing AI products and extending asset-light services; no quantitative financial targets were stated.

• Plans include regional collaborative centers targeting coverage of 5–8 counties and townships each, mobile imaging services and an enterprise-level trusted medical data space in 2026.

• Remaining proceeds from the May 2025 placing are expected to be used by Dec. 31, 2026; remaining proceeds from the August placing by Dec. 31, 2028.